Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment. (July 2022)

• Record Type: Journal Article
• Authors: Kim, Hyemin; Im, Ilkyun; Jeon, Jang Su; Kang, Eun-Hye; Lee, Hyang-Ae; Jo, Seongyea; Kim, Ji-Woo; Woo, Dong-Hun; Choi, Young Jae; Kim, Hyo Jin; Han, Ji-Seok; Lee, Byoung-Seok; Kim, Jong-Hoon; Kim, Sang Kyum; Park, Han-Jin
• Is Part Of: Biomaterials. Volume 286(2022)
• Publication Date: 2022-07
• Subjects: Hepatic organoid -- Drug metabolism -- Toxicity testing -- Liver -- Cytochrome P450 -- Wilson's disease; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2022.121575
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Human in vitro hepatic models that faithfully recapitulate liver function are essential for successful basic and translational research. A limitation of current in vitro models, which are extensively used for drug discovery and toxicity testing, is the loss of drug metabolic function due to the low expression and activity of cytochrome P450 (CYP450) enzymes. Here, we aimed to generate human pluripotent stem cell-derived hepatic organoids (hHOs) with a high drug metabolic ability. We established a two-step protocol to produce hHOs from human pluripotent stem cells for long-term expansion and drug testing. Fully differentiated hHOs had multicellular composition and exhibited cellular polarity and hepatobiliary structures. They also displayed remarkable CYP450 activity and recapitulated the metabolic clearance, CYP450-mediated drug toxicity, and metabolism. Furthermore, hHOs successfully modeled Wilson's disease in terms of Cu metabolism, drug responses, and diagnostic marker expression and secretion. In conclusion, hHOs exhibit high capacity for drug testing and disease modeling. Hence, this hepatic model system provides an advanced tool for studying hepatic drug metabolism and diseases.